Company / Total Assets
Protalix BioTherapeutics, Inc. Total Assets History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$82.3M
FY2025
5-year range
$55.8M / $84.4M
FY2021-FY2025
Trend
+12.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has fluctuated over the past 10 years, ranging from $45M in FY2019 to $97M in FY2015.
Based on SEC 10-K filings.
$82M in FY2025 with a 10-year CAGR of -1.7%.
Declined from $84M to $82M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- +13.9%
- 5-Year CAGR
- +3.9%
- 10-Year CAGR
- -1.7%
Key checks
Key Insights
- 5-year CAGR of +3.9%, indicating consistent growth.
- In FY2025, total assets increased 12.2% year-over-year.
- Peak total assets was recorded in FY2015.
- Lowest total assets in the period was in FY2019.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $82.3M | +12.2% |
| FY2024 | $73.4M | -13.0% |
| FY2023 | $84.4M | +51.4% |
| FY2022 | $55.8M | -24.3% |
| FY2021 | $73.7M | +8.4% |
| FY2020 | $67.9M | +49.7% |
| FY2019 | $45.4M | -37.1% |
| FY2017 | $72.2M | -12.2% |
| FY2016 | $82.2M | -15.4% |
| FY2015 | $97.3M | +23.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026